Navamedic ASA Reports Double Digit Growth in Q3 2025
Navamedic ASA, a Nordic pharma company, has announced its Q3 2025 results, with revenues of NOK 138.9 million, representing a 12.9% increase from Q3 2024.
- Gross margin improved to 37.5%
- Adjusted EBITDA amounted to NOK 11.3 million
- Rx business area included NOK 10.6 million in revenues from the dne business
The company's revenues performance was driven by increases in all three business areas.
No specific quotes available in the text.
Author's summary: Navamedic ASA reports 12.9% revenue growth in Q3 2025.